VentriPoint Diagnostics Ltd (DE:5V7)
FRANKFURT:5V7
5V7 Stock Chart & Stats
€0.05
€0.02(31.15%)
At close: 4:00 PM EST
€0.05
€0.02(31.15%)
Day’s Range― - ―
52-Week Range€0.04 - €0.09
Previous CloseN/A
Volume10.00K
Average Volume (3M)0.00
Market Cap
€13.10M
Enterprise Value€25.07M
Total Cash (Recent Filing)€55.39K
Total Debt (Recent Filing)€2.60M
Price to Earnings (P/E)―
Beta-0.14
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding192,577,940
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-5.63
Price to Sales (P/S)128.71
P/FCF Ratio-14.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue AccelerationMaterial top-line acceleration indicates the company’s offerings are gaining traction and expanding market reach. Sustained revenue growth over multiple quarters would provide a durable foundation to achieve scale, improve unit economics, and justify incremental investment in commercial expansion.
High/Improving Gross MarginA ~66% gross margin signals strong product-level economics and pricing power versus direct costs. High gross margins create structural capacity to absorb operating expenses and eventually convert revenue growth into operating leverage if fixed costs are managed, supporting a durable path to profitability.
Improving Operating Cash Flow TrendSequential reduction in operating cash burn indicates management has begun curbing outflows or scaling revenue effectively. While still negative, an improving cash-flow trajectory is a durable operational signal that reduces near-term funding pressure and can extend runway if the trend continues.
Bears Say
Deeply Negative EquityNegative shareholders' equity is a structural capital weakness that limits financial flexibility and raises default and dilution risk. It constrains access to traditional financing, makes covenant-free debt harder to obtain, and elevates the likelihood of equity raises that dilute existing holders.
Rising Leverage With Thin Asset BaseIncreasing debt against a very small asset base raises solvency and liquidity risk over the medium term. Limited tangible assets reduce collateral availability, making future borrowing more expensive or dilutive and increasing the company’s vulnerability to funding shocks.
Persistent Operating LossesVery large operating losses relative to revenue indicate the company has not yet achieved operating leverage. Losses that translate into cash outflows make the business dependent on external financing, creating a recurring structural requirement for capital until profitability is reached.
5V7 FAQ
What was VentriPoint Diagnostics Ltd’s price range in the past 12 months?
VentriPoint Diagnostics Ltd lowest stock price was €0.04 and its highest was €0.09 in the past 12 months.
What is VentriPoint Diagnostics Ltd’s market cap?
VentriPoint Diagnostics Ltd’s market cap is €13.10M.
When is VentriPoint Diagnostics Ltd’s upcoming earnings report date?
VentriPoint Diagnostics Ltd’s upcoming earnings report date is Aug 28, 2026 which is in 62 days.
How were VentriPoint Diagnostics Ltd’s earnings last quarter?
Currently, no data Available
Is VentriPoint Diagnostics Ltd overvalued?
According to Wall Street analysts VentriPoint Diagnostics Ltd’s price is currently Overvalued.
Does VentriPoint Diagnostics Ltd pay dividends?
VentriPoint Diagnostics Ltd does not currently pay dividends.
What is VentriPoint Diagnostics Ltd’s EPS estimate?
VentriPoint Diagnostics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VentriPoint Diagnostics Ltd have?
VentriPoint Diagnostics Ltd has 192,577,940 shares outstanding.
What happened to VentriPoint Diagnostics Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of VentriPoint Diagnostics Ltd?
Currently, no hedge funds are holding shares in DE:5V7
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VentriPoint Diagnostics Ltd
VentriPoint Diagnostics Ltd. is a medical technology company focused on developing and commercializing diagnostic tools worldwide. These innovative solutions are designed to monitor individuals afflicted with cardiovascular disease. At the core of their offerings is the Ventripoint Medical System (VMS), an advanced medical imaging platform. The VMS generates precise three-dimensional models of the heart's chambers, providing crucial volumetric and functional measurements. This system is further enhanced by its VMS+ software, which processes echocardiogram and magnetic resonance imaging (MRI) data to construct these 3D models. The VMS+ software ensures highly reproducible and accurate quantification of heart chamber volumes and ejection fraction. Beyond its current flagship system, VentriPoint Diagnostics is actively expanding its portfolio with a suite of specialized applications. These applications target various cardiac conditions and imaging techniques, including congenital heart disease, pulmonary hypertension, cardiotoxicity in oncology patients, and heart complications stemming from Covid-19. Founded in 2004, the company operates from its headquarters in Toronto, Canada.
Technical Analysis
Options Prices
Currently, No data available
---